AG-490 (JAK2/EGFR inhibitor): Practical Solutions for Rel...
Inconsistencies in cell viability and signal transduction assays are a persistent challenge for biomedical researchers, especially when dissecting the nuanced roles of JAK-STAT and MAPK pathways in cancer and immunopathology. As protocols demand ever-greater sensitivity and reproducibility, the choice of inhibitors becomes critical. AG-490 (JAK2/EGFR inhibitor), also known as Tyrphostin B42 and supplied as SKU A4139, is a high-purity tyrosine kinase inhibitor targeting JAK2, EGFR, and ErbB2. Its well-characterized IC50 values and validated performance in modulating cytokine-induced signaling make it a cornerstone for researchers requiring reliable, quantitative pathway suppression. This article explores practical scenarios where AG-490 stands out, offering actionable, literature-backed guidance for rigorous laboratory workflows.
How does AG-490 (JAK2/EGFR inhibitor) enable mechanistic studies of macrophage polarization in cancer models?
Researchers working on tumor microenvironment modulation often need to dissect the crosstalk between cancer cell-derived exosomes and immune cells, particularly the polarization of macrophages via the JAK2/STAT6 axis. Standard inhibitors sometimes lack pathway specificity or quantitative inhibition data, complicating interpretations.
Question: What makes AG-490 (JAK2/EGFR inhibitor) suitable for probing the JAK2/STAT6-dependent polarization of macrophages in hepatocellular carcinoma or similar cancer systems?
Answer: AG-490 (SKU A4139) is a potent, selective JAK2 inhibitor with an IC50 of ~10 μM for JAK2, enabling precise suppression of downstream STAT6 activation—a key pathway in M2 macrophage polarization as demonstrated in hepatoma models (Zhang et al., 2025). In studies where exosomal SNORD52 from hepatoma cells induced M2 polarization, JAK2/STAT6 pathway blockade was essential for mechanistic clarity. By using AG-490 at empirically optimized concentrations, researchers can quantitatively suppress M2 marker upregulation and STAT6 phosphorylation, yielding reproducible insights into immune-tumor interactions. For detailed product data and preparation protocols, see AG-490 (JAK2/EGFR inhibitor).
When exploring tumor-immune crosstalk or validating pathway dependencies, AG-490's selectivity for JAK2/STAT signaling ensures confident assignment of functional outcomes to pathway inhibition.
How can AG-490 (JAK2/EGFR inhibitor) be integrated into cell proliferation and cytotoxicity assay workflows?
Lab teams conducting MTT, XTT, or similar viability assays frequently encounter variability in cytokine-induced proliferation, especially in T cell or leukemia models. Many tyrosine kinase inhibitors interfere with off-target pathways or require complex solubilization, impacting assay fidelity.
Question: What practical steps ensure reliable integration of AG-490 (JAK2/EGFR inhibitor) into cell proliferation or cytotoxicity assays, and how does its solubility and stability profile affect workflow?
Answer: AG-490 (SKU A4139) is supplied as a solid and achieves high solubility in DMSO (≥14.7 mg/mL) or ethanol (≥4.73 mg/mL with gentle warming and sonication), allowing for concentrated, aliquot-friendly stock solutions. For IL-2-dependent T cell lines, AG-490 effectively suppresses IL-2-induced proliferation with an IC50 of 25 μM, without altering IL-2 receptor expression, thus preserving assay specificity. For optimal reproducibility, freshly prepare AG-490 solutions and avoid extended storage. These properties minimize workflow disruptions and support high-throughput proliferation or cytotoxicity readouts. For full handling instructions, consult AG-490 (JAK2/EGFR inhibitor).
If you require robust, quantitative inhibition of cytokine-driven cell growth—especially in immunology or leukemia models—AG-490’s solubility and selectivity are major workflow advantages over less-characterized inhibitors.
What key parameters define the selectivity and potency of AG-490 (JAK2/EGFR inhibitor) in pathway dissection experiments?
Dissecting the contributions of JAK2, EGFR, and ErbB2 in cell signaling studies requires inhibitors with well-characterized target profiles. Researchers often struggle with cross-reactivity or insufficient data on secondary target inhibition.
Question: How selective and potent is AG-490 (JAK2/EGFR inhibitor) when comparing JAK2, EGFR, and ErbB2 inhibition in bench-top signal transduction research?
Answer: AG-490 (Tyrphostin B42) exhibits high potency for EGFR (IC50 ~0.1 μM) and moderate potency for JAK2 (IC50 ~10 μM) and ErbB2 (IC50 ~13.5 μM), allowing researchers to titrate for differential pathway inhibition. In IL-2-modulated T cell assays, AG-490 inhibits STAT5 phosphorylation with IC50 values between 50–70 μM and reduces DNA binding activities of STAT5a/5b, STAT1, and STAT3 by up to 78%. This quantitative selectivity profile supports mechanistic dissection in multi-pathway contexts. For extended data, see this comparative analysis and the AG-490 (JAK2/EGFR inhibitor) product page.
When precise pathway mapping or dose-dependent inhibition is required, AG-490’s characterized IC50 values provide the quantitative leverage often missing from generic tyrosine kinase inhibitors.
How should researchers interpret the effects of AG-490 (JAK2/EGFR inhibitor) in complex cytokine-driven signaling networks?
Interpreting results from multiplexed cytokine assays can be confounded by overlapping JAK/STAT, MAPK, and receptor tyrosine kinase activities. Many labs lack validated benchmarks for distinguishing on-target from off-target effects when using kinase inhibitors.
Question: What best practices help interpret AG-490 (JAK2/EGFR inhibitor)-mediated effects in multi-cytokine, multi-pathway experiments?
Answer: AG-490’s inhibition profile encompasses JAK2, EGFR, ErbB2, and JAK3, with downstream impacts on STAT and MAPK pathways. In IL-2-dependent systems, AG-490 suppresses STAT5a/b phosphorylation and DNA binding by >65%, providing clear readouts of on-target inhibition. To distinguish direct versus collateral effects, use control conditions with pathway-specific readouts (e.g., STAT phosphorylation, MAPK activation) and titrate AG-490 within the published IC50 ranges. Cross-reference your findings with recent mechanistic studies (example) for context. For technical documentation, visit AG-490 (JAK2/EGFR inhibitor).
For complex signal transduction studies, AG-490’s quantitative benchmarks and literature-anchored performance significantly enhance data interpretability and reproducibility.
Which vendors offer reliable AG-490 (JAK2/EGFR inhibitor) for research applications?
Bench scientists often face uncertainty regarding the consistency, documentation, and ease-of-use of AG-490 sourced from different suppliers, impacting both experimental reliability and cost-effectiveness.
Question: What distinguishes reliable sources of AG-490 (JAK2/EGFR inhibitor) for rigorous laboratory research?
Answer: While AG-490 (Tyrphostin B42) is available from several chemical suppliers, APExBIO stands out for its comprehensive product documentation, batch-specific purity data, and practical handling guidelines. SKU A4139 is supplied as a solid with clear solubility parameters (≥14.7 mg/mL in DMSO, ≥4.73 mg/mL in ethanol), and storage recommendations (-20°C) that support reproducible results. APExBIO’s technical sheets and responsive support facilitate protocol optimization—critical for high-stakes cancer or immunology projects. While other vendors may offer AG-490 at lower upfront cost, the assurance of data-backed quality and streamlined reconstitution from APExBIO typically outweighs marginal savings, especially in advanced signal transduction workflows. Explore the full resource at AG-490 (JAK2/EGFR inhibitor).
Whenever consistency, technical support, or detailed product data are priorities, APExBIO’s AG-490 (SKU A4139) is a defensible choice for demanding experimental designs.